Posts tagged TSX:AUP
Aurinia plans single Phase 3 trial of voclosporin in LN

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) plans to initiate a single Phase 3 clinical trial (Aurora), with a design consistent with that of the continuing Aura-LV clinical trial of voclosporin for the treatment of lupus nephritis (LN).

Read More
Aurinia’s voclosporin meets 48-week remission endpoints

Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) Phase 2b AURA-LV study of voclosporin in lupus nephritis (LN) met its complete and partial remission (CR/PR) endpoints at 48 weeks.

Read More
Richard Glickman adds CEO title at Aurinia

Richard Glickman, founder and chairman of Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP), was named to the added post of CEO. The board also accepted the resignation of Charles Rowland as CEO and an executive member of the board, effective immediately.

Read More
Leerink reiterates outperform rating on Aurinia post-data

Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the company reported additional positive data for its voclosporin drug candidate in patients with active lupus nephritis.

Analyst Joseph Schwartz writes that data presented today at the European Lupus Meeting showed that 70% of patients (seven-of-10) achieved complete remission (CR) at 24 weeks, compared with 57% (four-of-seven patients) reported in July.

Read More
Aurinia posts positive Phase 2b voclosporin results

Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) voclosporin achieved its primary endpoint of complete remission (CR) at 24 weeks in a Phase 2b trial.

In addition, when both doses of voclosporin were added to the current standard of care of mycophenolate mofetil and a forced oral corticosteroid taper, voclosporin met all 24-week prespecified secondary endpoints versus the control group.

Read More
Leerink reiterates rating on Aurinia following trial results

Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the reported top-line results with voclosporin in a Phase 2b clinical study in patients with active lupus nephritis.

Analyst Joseph Schwartz writes that the study met its primary endpoint of complete remission and improvements in partial remission versus placebo. While efficacy was higher among patients receiving the low-dose, the high-dose cohort also achieved meaningful improvements in partial remission.

Read More